Association between the DRD2-141C Insertion/Deletion polymorphism and schizophrenia

Epidemiological studies have demonstrated that the genetic component is an important risk factor for the development of schizophrenia. The genes that codify the different compounds of the dopaminergic system have created interest for molecular investigations in patients with schizophrenia because the antipsychotic drugs, especially those of first generation, act on this cerebral system. Thus the aim of the present study was to investigate the possible association between the -141 Ins/Del (rs1799732) polymorphism of the dopamine receptor type 2 (DRD2) and schizophrenia. The distribution of the alleles and genotypes of the studied polymorphism was investigated in a sample of 229 patients and 733 controls. There were statistical differences in the allelic (χ2=9.78; p=0.001) and genotypic genotypic (χ2=12.74; p=0.001) distributions between patients and controls. Thus the -141C Ins/Del polymorphism of the DRD2 gene (allele Ins) was associated to the SCZ phenotype in the investigated sample.

Download Full-text

Association between the SLC6A3 A1343G polymorphism and schizophrenia

Arquivos de Neuro-Psiquiatria ◽

10.1590/s0004-282x2010000500008 ◽

2010 ◽

Vol 68 (5) ◽

pp. 716-719 ◽

Cited By ~ 14

Author(s):

Quirino Cordeiro ◽

Jacqueline Siqueira-Roberto ◽

Homero Vallada

Keyword(s):

Single Nucleotide Polymorphism ◽

Risk Factor ◽

First Generation ◽

Antipsychotic Drugs ◽

Dopaminergic System ◽

Epidemiological Studies ◽

Nucleotide Polymorphism ◽

Single Nucleotide ◽

Gender And Age ◽

Exon 9

Epidemiological studies have demonstrated that the genetic component is an important risk factor for the development of schizophrenia. The genes that codify the different compounds of the dopaminergic system have created interest for molecular investigations in patients with schizophrenia because the antipsychotic drugs, especially those of first generation, act on this cerebral system. Thus the aim of the present study was to investigate the possible association between a new single nucleotide polymorphism (rs6347) located in exon 9 of the protein transporter (SLC6A3) and schizophrenia. The distribution of the alleles and genotypes of the studied polymorphism was investigated in a sample of 235 patients and 834 controls matched by gender and age. There were statistical differences in the allelic (χ2=5.97, 1d.f. , p=0.01, OR=1.33-1.05<OR<1.69) and genotypic (χ2=6.56, 2d.f. , p=0.03) distributions between patients and controls. Thus the SLC6A3 A1343G polymorphism was associated to the SCZ phenotype in the investigated sample.

Download Full-text

Human non-functioning pituitary tumors invasiveness: inhibitory effects of dopamine receptor type 2 (DRD2) agonist and cofilin involvement

Endocrine Abstracts ◽

10.1530/endoabs.41.ep853 ◽

2016 ◽

Author(s):

Erika Peverelli ◽

Elena Giardino ◽

Donatella Treppiedi ◽

Marco Locatelli ◽

Valentina Vaira ◽

...

Keyword(s):

Dopamine Receptor ◽

Pituitary Tumors ◽

Receptor Type ◽

Inhibitory Effects

Download Full-text

Synonymous polymorphism rs201256011 in dopamine receptor type 2 gene is associated with schizophrenia and PANSS score in Pakistani population: A first report

International Journal of Clinical Practice ◽

10.1111/ijcp.13536 ◽

2020 ◽

Vol 74 (9) ◽

Author(s):

Qurat‐ul‐Ain Amir ◽

Farina Hanif ◽

Washdev Washdev ◽

Fareena Bilwani ◽

Shabana Usman Simjee

Keyword(s):

Dopamine Receptor ◽

Receptor Type ◽

Pakistani Population ◽

First Report ◽

Synonymous Polymorphism

Download Full-text

Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies

European Psychiatry ◽

10.1016/j.eurpsy.2004.11.003 ◽

2005 ◽

Vol 20 (1) ◽

pp. 15-27 ◽

Cited By ~ 114

Author(s):

Anissa Abi-Dargham ◽

Marc Laruelle

Keyword(s):

First Generation ◽

Antipsychotic Drugs ◽

Second Generation ◽

Dopaminergic System ◽

Therapeutic Strategies ◽

Therapeutic Action ◽

Imaging Studies ◽

High Incidence ◽

Second Generation Antipsychotic ◽

Clinically Significant

AbstractMultiple lines of evidence including recent imaging studies suggest that schizophrenia is associated with an imbalance of the dopaminergic system, entailing hyperstimulation of striatal dopamine (DA) D2 receptors and understimulation of cortical DA D1 receptors. This DA endophenotype presumably emerges from the background of a more general synaptic dysconnectivity, involving alterations in N-methyl-d-aspartate (NMDA) and glutamatergic (GLU) functions. Equally important is the fact that this DA dysregulation might further impair NMDA transmission. The first generation antipsychotic (FGA) drugs are characterized by high affinity to and generally high occupancy of D2 receptors. The efficacy of FGAs is limited by a high incidence of extrapyramidal side-effects (EPS). Second generation antipsychotic (SGA) drugs display reduced EPS liability and modest but clinically significant enhanced therapeutic efficacy. Compared to FGAs, the improved therapeutic action of SGAs probably derives from a more moderate D2 receptor blockade. We will review the effects of SGAs on other neurotransmitter systems and conclude by highlighting the importance of therapeutic strategies aimed at directly increasing prefrontal DA, D1 receptor transmission or NMDA transmission to enhance the therapeutic effect of moderate D2 receptor antagonism.

Download Full-text